Supreme Court Rejects Roundup Cancer Claims, Curbing Bayer Liability in Glyphosate Cases

The ruling centered on federal preemption under FIFRA, holding that state failure-to-warn claims conflict with EPA's determination that glyphosate is not likely carcinogenic to humans. This overrides jury verdicts from earlier trials where plaintiffs cited IARC's 2015 classification of glyphosate as a probable human carcinogen based on limited evidence in humans and sufficient evidence in animals. The decision distinguishes regulatory labeling from tort liability but leaves open questions about post-approval data reviews.

Glyphosate litigation has involved over 100,000 claims since Bayer's 2018 Monsanto acquisition, with prior settlements exceeding $10 billion. Observational studies, such as the Agricultural Health Study cohort of 54,000 applicators, found no clear dose-response link to NHL after adjustment for confounders, contrasting with smaller case-control studies showing modest odds ratios around 1.4. The Court's emphasis on EPA's 2017 and 2020 risk assessments highlights how agency conclusions can insulate manufacturers when they diverge from IARC monographs.

Broader patterns show this fits a trend of federal courts narrowing state tort actions in pesticide and pharmaceutical cases, potentially reducing incentives for post-market safety signals. Public trust in product safety may erode further if communities perceive regulatory capture, as seen in prior asbestos and PCB litigations. State attorneys general may respond with labeling mandates or procurement restrictions.

Next steps include district courts applying the precedent to pending multidistrict litigation and possible congressional efforts to clarify FIFRA preemption scope. Bayer's exposure is materially reduced, though European reauthorization reviews continue through 2031.